Nuvectis Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVCT research report →
About the company
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer.
- CEO
- Ron Bentsur
- IPO
- 2022
- Employees
- 13
- HQ
- Fort Lee, NJ, US
Price Chart
- Market Cap
- $519.32M
- P/E
- -14.94
- P/S
- 0.00
- P/B
- 32.22
- EV/EBITDA
- -17.61
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -147.78%
- ROIC
- -198.78%
- Revenue
- $0 · 0.00%
- Net Income
- $-26,442,000 · -39.17%
- EPS
- $-1.32 · -18.92%
- Op Income
- $-27,574,000
- FCF YoY
- -30.72%
- 52W High
- $29.27
- 52W Low
- $5.55
- 50D MA
- $12.36
- 200D MA
- $8.70
- Beta
- -0.25
- Avg Volume
- 227.60K
Get TickerSpark's AI analysis on NVCT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Mosseri Marlio Charles | buy | 50,000 |
| Jun 30, 26 | BENTSUR RON | buy | 12,500 |
| Jun 11, 26 | Hoberman Kenneth | other | 35,000 |
| Jun 11, 26 | Oliviero James F III | other | 35,000 |
| Jun 11, 26 | Sanchez Juan | other | 35,000 |
| Jun 11, 26 | Kaplan Matthew L. | other | 35,000 |
| Jan 6, 26 | Shemesh Shay | other | 150,000 |
| Jan 6, 26 | BENTSUR RON | other | 150,000 |
| Jan 6, 26 | Poradosu Enrique | other | 150,000 |
| Jan 6, 26 | Carson Michael J. | other | 61,200 |
Our NVCT coverage
Recent articles, reports, and earnings notes.
No research on NVCT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NVCT report →Similar companies
Peers in the same neighborhood.